Reactivity between Herpesvirus Type 2-Related Soluble Cervical Tumor Cell Membrane Antigens and Matched Cancer and Control Sera

Hollinshead, Ariel C.; Lee, O. B.; McKELWAY, W P; Melnick, J. L.; Rawls, W E

doi:10.3181/00379727-141-36853

Cited by 28 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…That women with cervical cancer have a higher incidence of HSV II antibodies is well known. The percentage of such women with antibodies to HSV II described varies from report to report and with dif ferent detection methods [Kawana et al, 1974], ranging from 31 to 95% [Petersen et al, 1975;Hollinshead et al, 1972]. There is a possibility that at least some tumorassociated immune reactions are due to reactions to HSV II antigens in biopsies of cervical carcinoma tissue.…”

Section: Discussionmentioning

confidence: 99%

Cell-Mediated Immunity in Patients with Cervical Cancer

Cerni¹,

Tatra²,

Berger³

et al. 1979

Oncology

View full text Add to dashboard Cite

In 16 patients with cervical carcinoma (stages II and III) tumor-specific and general immune reactivity was investigated. Cancer patients’ skin reactivity was different from that of controls insofar as there was a decreased response to streptokinase-streptodornase as well as to DNCB. Absence of DNCB sensitization was mainly in stage III patients. Cell-mediated immunity to autologous and/or allogeneic tumor-associated antigens (TAA) was demonstrated in vivo and in vitro. 3 of 8 patients had positive skin reactions to autologous TAA and 8 of 14 reacted to allogeneic TAA. In the lymphocyte migration inhibition test, 8 of 14 patients reacted to autologous tumor membrane preparations and 3 of 10 to allogeneic pooled preparations. In addition, there was some indication of cross-reaction with antigens from a human squamous cell carcinoma of the lung. There was no reaction in vitro to normal cervical tissue and no association between tumor-specific reactions and herpes simplex virus type II antibodies could be demonstrated. Patients with DNCB sensitization and in vivo as well as in vitro lymphocyte reactivity to TAA had a better prognosis than nonreacting patients, indicating the value of combined immunological tests.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell-Mediated Immunity in Patients with Cervical Cancer

Cerni¹,

Tatra²,

Berger³

et al. 1979

Oncology

View full text Add to dashboard Cite

show abstract

“…Antigenic relationships between HSV-2 and the HSV-2 associated hamster tumors were suggested earlier by anticomplement immunofluorescent (ACIF) tests (8) which also pointed to a relation between HSV-2 and cervical cancer. Using different serological tests, other workers have also found antigenic relationships between this virus and human cancer (9,10). Further work is in progress to characterize the antigens common to the virus and the hamster or human tumors.…”

Section: Reciprocal Titers Obtainedmentioning

confidence: 97%

Common Antigens of Herpes Simplex Virus 2, Associated Hamster Tumors, and Human Cervical Cancer

Ibrahim¹,

Ray²,

Megaw³

et al. 1976

Experimental Biology and Medicine

View full text Add to dashboard Cite

“…Xenoantibodies to cRNA virus have been produced and found to interact with a specific cell surface antigen common to murine and feline leukemias [30]. In the case of DN A virus-induced tumors the membrane antigen will probably be a non-virion antigen necessitating the use of the latter as the source of antibodies [18] There appears to be a possibility that the ultimate in purification may not be as important for the leukemias and free-floating metastatic cells as for solid tumors because, where the tumor cells are in the blood, they will be exposed to radioantibodies immediately after injection and before exposure of the normal tissues (other than normal blood cells), so that if amounts of radioantibodies just sufficient to bind to the tumor cells (table III) are injected slowly enough to allow all of the blood to be exposed to the radioantibodies before reaching normal tissues, then availability of the radioantibodies to the normal tissues will be much decreased, with a corresponding increase in specificity. For this reason, the leukemias and free-floating metastases may be more amenable to immuno radiotherapy by presently available xenoantibody techniques than may solid tumors.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of Tumor Immunoradiotherapy Using Radioiodinated Antibodies to Tumor-Specific Cell Membrane Antigens with Emphasis on Leukemias and Early Metastases

McGaughey¹

1974

Oncology

View full text Add to dashboard Cite

Theoretical calculations and published data suggest that it is possible to deliver a highly therapeutic dose (500 rad) of β-radiation to individual free floating tumor cells solely by means of ¹³¹I- or ¹³³I-radiantibodies attached to tumor-specific antigens on the cell membrane over one half life of either isotope. The number of specific antigenic sites on tumor cells is apparently hundreds of times greater than the number of radioantibodies required to deliver the dose. Such an approach may be especially useful for destroying low numbers of leukemia cells or early metastases, but it might also be used for the therapy of disseminated tumors with adequate purification of and accessibility to antibodies. Other calculations showed that it is possible to deliver 500 rad to the blood as a whole using tumor-specific radioiodinated antibodies while keeping tissue toxicity at easily tolerated levels assuming that nonspecific adsorption to normal tissues can be discounted. The possible therapeutic potential of various methodological approaches was considered in the light of published findings.

show abstract

Reactivity between Herpesvirus Type 2-Related Soluble Cervical Tumor Cell Membrane Antigens and Matched Cancer and Control Sera

Cited by 28 publications

References 0 publications

Cell-Mediated Immunity in Patients with Cervical Cancer

Cell-Mediated Immunity in Patients with Cervical Cancer

Common Antigens of Herpes Simplex Virus 2, Associated Hamster Tumors, and Human Cervical Cancer

Feasibility of Tumor Immunoradiotherapy Using Radioiodinated Antibodies to Tumor-Specific Cell Membrane Antigens with Emphasis on Leukemias and Early Metastases

Contact Info

Product

Resources

About